H Lundbeck A/S

Research H Lundbeck A/S (0ND5) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker0ND5
• ExchangeLSE
• CountryDenmark
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyDKK
• Financial periodFY2025
• RevenueDKK 24.63B
• Revenue growth11.9%
• Net incomeDKK 3.19B
• Free cash flowDKK 4.93B
• Gross margin82.7%

About H Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.

Frequently asked questions

What does H Lundbeck A/S do?

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.